LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

LLY

759.75

-0.52%↓

JNJ

176.59

+0.08%↑

ABBV

220.03

+1.83%↑

UNH

341.1

+0.38%↑

AZN

77.6

-0.01%↓

Search

REVOLUTION Medicines Inc

Geschlossen

BrancheGesundheitswesen

44.02 -1.52

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

43.72

Max

45.15

Schlüsselkennzahlen

By Trading Economics

Einkommen

-34M

-248M

EPS

-1.13

Gewinnspanne

-74.379

Angestellte

700

EBITDA

-24M

-261M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+54.2% upside

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

750M

7.7B

Vorheriger Eröffnungskurs

45.54

Vorheriger Schlusskurs

44.02

Nachrichtenstimmung

By Acuity

33%

67%

113 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bullish Evidence

REVOLUTION Medicines Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

16. Sept. 2025, 17:03 UTC

Wichtige Markttreiber

BrainsWay Shares Rise on FDA Clearance of Major Depressive Disorder Treatment

16. Sept. 2025, 16:49 UTC

Wichtige Markttreiber
Akquisitionen, Fusionen, Übernahmen

GD Culture Shares Drop After Deal for Pallas Capital

16. Sept. 2025, 16:11 UTC

Wichtige Markttreiber

Corbus Shares Rise on FDA Fast-Track Designation for Cancer Drug

16. Sept. 2025, 23:40 UTC

Market Talk

Nikkei May Decline as Yen Strengthens -- Market Talk

16. Sept. 2025, 23:34 UTC

Market Talk

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

16. Sept. 2025, 23:20 UTC

Market Talk

Restaurant Brands NZ Can Outperform When Cycle Turns -- Market Talk

16. Sept. 2025, 21:10 UTC

Akquisitionen, Fusionen, Übernahmen

U.S. Investors, Trump Close In on TikTok Deal With China -- WSJ

16. Sept. 2025, 20:51 UTC

Market Talk

U.S. Home Sales, New Home Listings Fall in August -- Market Talk

16. Sept. 2025, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

16. Sept. 2025, 20:50 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Basic Materials Roundup: Market Talk

16. Sept. 2025, 20:25 UTC

Ergebnisse

The AI Trade Has Stocks Near Highs Again. Some Tech Names Remain on the Sidelines -- Barrons.com

16. Sept. 2025, 20:24 UTC

Ergebnisse

These Stocks Moved the Most Today: Oracle, Tesla, Alphabet, Dave & Buster's, Chipotle, and More -- Barrons.com

16. Sept. 2025, 19:19 UTC

Market Talk

U.S. Natural Gas Futures Extend Winning Streak -- Market Talk

16. Sept. 2025, 18:52 UTC

Market Talk

Oil Futures Advance on Russia Concerns, Weak Dollar -- Market Talk

16. Sept. 2025, 18:44 UTC

Market Talk

Global Equities Roundup: Market Talk

16. Sept. 2025, 18:44 UTC

Market Talk

EssilorLuxottica Well-Positioned in Growing Smart-Glasses Market -- Market Talk

16. Sept. 2025, 18:40 UTC

Akquisitionen, Fusionen, Übernahmen

Details Emerge on U.S.-China TikTok Deal -- WSJ

16. Sept. 2025, 18:38 UTC

Market Talk

Meta Seen With Long-Term Opportunity to Lead in Smart Glasses -- Market Talk

16. Sept. 2025, 18:19 UTC

Market Talk

Gold Settles at New High Ahead of Fed Decision -- Market Talk

16. Sept. 2025, 18:01 UTC

Market Talk

U.S. Dollar Weakness Supports Oil's Gains -- Market Talk

16. Sept. 2025, 17:34 UTC

Market Talk

Any Question the Bank of Canada Will Cut Now Look to Have Vanished -- Market Talk

16. Sept. 2025, 16:53 UTC

Ergebnisse

Software Companies Are Fighting Back With AI. The Stocks Are Still Hurting. -- Barrons.com

16. Sept. 2025, 16:20 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Basic Materials Roundup: Market Talk

16. Sept. 2025, 16:15 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Global Commodities Roundup: Market Talk

16. Sept. 2025, 16:09 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Global Energy Roundup: Market Talk

16. Sept. 2025, 16:09 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Canada Industry Minister to Meet Mining CEOs on Merger -- Market Talk

16. Sept. 2025, 15:35 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16. Sept. 2025, 15:35 UTC

Market Talk

Gold Soars Past $3,700 Ahead of Fed Decision -- Market Talk

16. Sept. 2025, 15:22 UTC

Market Talk

More Investors Think Dollar is Overvalued in Latest BofA Survey -- Market Talk

16. Sept. 2025, 15:21 UTC

Market Talk

Sterling Considered Most Overvalued in Nearly 10 Years -- Market Talk

Peer-Vergleich

Kursveränderung

REVOLUTION Medicines Inc Prognose

Kursziel

By TipRanks

54.2% Vorteil

12-Monats-Prognose

Durchschnitt 71.24 USD  54.2%

Hoch 80 USD

Tief 37.91 USD

Basierend auf 15 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für REVOLUTION Medicines Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

15 ratings

15

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

40.67 / 41.96Unterstützung & Widerstand

Kurzfristig

Strong Bullish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

113 / 371 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
help-icon Live chat